Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 9/20 | 0.60 |
| ▸ | CA1 | P00915 | 9/20 | 0.60 |
| ▸ | CA2 | P00918 | 9/20 | 0.60 |
| ▸ | CA4 | P22748 | 9/20 | 0.60 |
| ▸ | CA7 | P43166 | 9/20 | 0.60 |
| ▸ | CA9 | Q16790 | 9/20 | 0.60 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.45 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1401978 | 1.00 | CA12 (0.60) | CA12CA1CA2CA4CA7 | |
| SCHEMBL1401981 | 1.00 | CA12 (0.60) | CA12CA1CA2CA4CA7 | |
| SCHEMBL3156635 | 0.93 | ALDH1A1 (0.54) | CA12CA1CA2CA4CA7 | |
| Trifluoroacetic Acid SCHEMBL589490 | 0.93 | CA12 (0.54) | CA12CA1CA2CA4CA7 | |
| Trifluoroacetic Acid SCHEMBL3144597 | 0.93 | CA12 (0.54) | CA12CA1CA2CA4CA7 | |
| Hydrochloric Acid SCHEMBL2891561 | 0.92 | ALDH1A1 (0.53) | CA12CA1CA2CA4CA7 | |
| SCHEMBL1908653 | 0.88 | CA12 (0.57) | CA12CA1CA2CA4CA7 | |
| SCHEMBL1908761 | 0.88 | CA12 (0.57) | CA12CA1CA2CA4CA7 | |
| Hydrochloric Acid SCHEMBL2883478 | 0.86 | LMNA (0.49) | CA12CA1CA2CA4CA7 | |
| Trifluoroacetic Acid SCHEMBL2889125 | 0.86 | DPP4 (0.50) | CA12CA1CA2CA4CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1805181-B1 | PURINE DERIVATIVES FOR USE AS ADENOSIN A-2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2012-08-29 | — | — | EP | disclosed |
| US-8163754-B2 | inflammatory or obstructive airways diseases; in combination with an antiinflammatory, bronchodilatory, antihistamine or anti-tussive; N-[4-(6-Amino-2-phenethylamino-purin-9-yl)-2,3-dihydroxy-cyclopentyl]-propionamide | NOVARTIS AG (CH) | 2012-04-24 | — | — | US | disclosed |
| EP-2292619-A1 | Purine derivatives for use as adenonsin A-2A receptor agonists | Novartis AG (CH) | 2011-03-09 | — | — | EP | disclosed |
| US-20090105476-A1 | Organic Compounds | NOVARTIS AG | 2009-04-23 | — | — | US | disclosed |
| EP-2012760-A2 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | Novartis AG (CH) | 2009-01-14 | — | — | EP | disclosed |
| US-20080200483-A1 | Purine Derivatives for Use as Adenosin A-2A Receptor Agonists | NOVARTIS AG (CH) | 2008-08-21 | — | — | US | disclosed |
| WO-2007121921-A2 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2007-11-01 | — | — | WO | disclosed |
| EP-1805181-A1 | PURINE DERIVATIVES FOR USE AS ADENOSIN A-2A RECEPTOR AGONISTS | Novartis AG (CH) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006045552-A1 | PURINE DERIVATIVES FOR USE AS ADENOSIN A-2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200483-A1 | Purine Derivatives for Use as Adenosin A-2A Receptor Agonists | ADORA2A, ADORA1, ADORA3 | CA12 4138/4885CA1 4030/4885CA2 1804/4885 |
| US-20090105476-A1 | Organic Compounds | CYP3A43, SLCO1B3, CYP2C19 | CA12 1400/4885CA1 3204/4885CA2 2138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.